MK-677 (Ibutamoren) tracker
Educational reference for MK-677 (Ibutamoren). Use it inside TrackPep to log doses, side effects, and rotation sites.
Half-life
24 h
Tmax
1 h
Category
peptide
Also known as: ibutamoren, MK-0677, nutrobal
> PLACEHOLDER — pending clinical review by licensed pharmacist. MK-677 (ibutamoren) is an orally active growth hormone secretagogue (ghrelin receptor agonist). Investigational; not FDA-approved. Taken orally.
Mechanism
MK-677 (ibutamoren) is an orally active, non-peptide ghrelin receptor (GHS-R1a) agonist that stimulates growth-hormone and IGF-1 secretion. Unlike peptide secretagogues, it is absorbed orally.
Research summary
Studied in clinical trials as a growth-hormone secretagogue, including in older adults and in the context of body composition. It is not FDA-approved, and long-term outcome data are limited.
Dosing in the literature
Trials used oral administration under study protocols. There is no approved clinical regimen; this summary does not provide dosing.
Reported side effects
Reported effects include increased appetite, water retention, transient increases in blood glucose and insulin resistance, and fatigue. Effects on growth hormone and IGF-1 warrant monitoring. The full profile is not established.
Stacking notes
Discussed in growth-hormone secretagogue contexts; any combination is a clinical/experimental decision. Effects on glucose metabolism are a relevant consideration.
Educational summary of published research. Not dosing guidance or medical advice.
Sources
- MK-677 (ibutamoren) growth-hormone secretagogue trials · peer-reviewed clinical trials (1998)search PubMed for MK-677 ibutamoren
- Regulatory status note · FDA / regulatory guidance (2024)not an approved drug; verify current status
Track MK-677 (Ibutamoren) in TrackPep
Reconstitution calculator, interactive body-map rotation, side-effect timeline, weight trends, and a private log — all in one place. Free to try.